In this webinar Catalent experts outline cell line development, upstream process development and process scale-up for Catalent’s SMARTag® technology antibody programs in which the antibody requires additional conversion by a site-specific enzyme for correct functionality.
Moving A Complex Protein From Development To Large-Scale Clinical Production
Summary: The number of more complex biopharmaceuticals in development continues to increase. These include molecules like virus-like particle vaccines, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, and more recently, numerous different multi-specific antibody platforms. Each of these classes of molecules requires multiple proteins to be expressed at differing ratios to get the correct biopharmaceutical produced at maximum titer and quality..